Northwest Bioth Cmn (NWBO): Price and Financial Metrics
NWBO Price/Volume Stats
| Current price | $0.48 | 52-week high | $1.09 |
| Prev. close | $0.46 | 52-week low | $0.40 |
| Day low | $0.46 | Volume | 1,098,100 |
| Day high | $0.49 | Avg. volume | 1,723,885 |
| 50-day MA | $0.53 | Dividend yield | N/A |
| 200-day MA | $0.64 | Market Cap | 574.42M |
NWBO Stock Price Chart Interactive Chart >
Northwest Bioth Cmn (NWBO) Company Bio
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.
Latest NWBO News From Around the Web
Below are the latest news stories about NORTHWEST BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate NWBO as an investment opportunity.
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For GlioblastomaNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer. |
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization ApplicationNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma. |
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization ApplicationNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about its progress toward submission of a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma. |
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory BoardNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). |
Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization ApplicationNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that it plans to submit a Marketing Authorization Application (MAA) in the U.K., to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA), for commercial approval of the Company's DCVax®-L treatment for glioblastoma. |
NWBO Price Returns
| 1-mo | -20.00% |
| 3-mo | -19.60% |
| 6-mo | -36.84% |
| 1-year | -1.54% |
| 3-year | -68.56% |
| 5-year | 72.10% |
| YTD | -31.53% |
| 2023 | -10.64% |
| 2022 | 12.07% |
| 2021 | -54.10% |
| 2020 | 609.63% |
| 2019 | 4.57% |
Continue Researching NWBO
Want to do more research on Northwest Biotherapeutics Inc's stock and its price? Try the links below:Northwest Biotherapeutics Inc (NWBO) Stock Price | Nasdaq
Northwest Biotherapeutics Inc (NWBO) Stock Quote, History and News - Yahoo Finance
Northwest Biotherapeutics Inc (NWBO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...